Table 3.
The main bioactive compounds found in the AbM, doses and administration routes, and target functions.
| Bioactive substances | Components | Dose and/or administration route | Function | References |
|---|---|---|---|---|
| Polysaccharide | AbM polysaccharides (AbMP) | 100, 150, and 200 mg/kg BW; oral | Immunoregulation | Li and Wei (2017) |
| Polysaccharide | AbEXP1-a | 0.2 mL/kg BW; ingest | Anti-fatigue | LI (2020) |
| Polysaccharide | AbMP | 100, 150, and 200 mg/kg BW; gavage | Anti-fatigue | Li and Wei (2017) |
| Polysaccharide | β-Glucans | 2% β-Glucans; oral | Anti-diabetic | Kim et al. (2005) |
| Polysaccharide | β-Glucans | 0.5 mg/mL AbM water extract; oral | Antitumor | Murakawa et al. (2007) |
| Polysaccharide | AbMP | 4% and 8% | Hyperglycemia | Duan and Ma (2005) |
| Polysaccharide | AbMP (AbMP-F, AbMP-V, AbMP-A) | 300, 600, and 900 μg/mL (in vitro) | Antioxidant | Wu et al. (2014) |
| Polysaccharide | Acid-treated fraction (ATF) | 1 mg; injected intratumorally | Antitumor | Fujimiya et al. (1998) |
| Polysaccharide | AbM polysaccharides (AbMP) | 40, 80 and 160 mg/kg;intraperitoneal injection | Anti-inflammatory | Zhao et al. (2004) |
| Polysaccharide | AbMP-Ⅱ-α and AbMP-Ⅱ-β | 50, 100 and 200 μg/mL of AbMP-Ⅱ-α and 5.8, 29 and 145 μg/mL AbMP-Ⅱ-β (in vitro) | Anticarcinogenic | SHEN, SUN, LIU & GU (2001) |
| Polysaccharide | FI0-a-β, FA-1-a-⍺, FA-a-β and FA-2-b-β | 10 mg/kg BW; Intraperitoneal injection | Antitumor | Mizuno et al. (1990) |
| Polysaccharide | AbMP (Mw 058 × 103 ku) | 62.5, 125, 250, 500 and 1000 μg/mL (in vitro) | Anti-inflammatory | Liu et al. (2017) |
| Polysaccharide-protein complex | Antitumor organic substance Mie (ATOM) | 10 and 20 mg/kg/day and 50 and 100 mg/kg/day; subcutaneous | Antitumor | Ito et al. (1997) |
| AbM extracts | – | 8 mg/mL EE and EA (in vitro) | Antidiabetic | Wei et al. (2019) |
| AbM extracts | – | 0.5 g/kg; oral | Antioxidant | Al-Dbass, Al- Daihan & Bhat, (2012) |
| AbM extracts | – | 250 and 500 mg/kg BW; oral | Hepatoprotective | Muthulingam et al. (2016) |
| AbM extracts | – | 10 μL AbM aqueous; oral | Antibacterial | Bernardshaw et al. (2005) |
| AbM extracts | – | 0.025 g/mL; orally gavage | Antimutagenic | Delmanto et al. (2001) |
| AbM extracts | AbMP | 3.58 ± 0.13 g/L;gavage | Hepatoprotective | ZHANG, LIN, DONG, WANG & HAN, (2016) |
| AbM extracts | – | 100 μL AbM aqueous (in vitro) | Antioxidant | HAKIME-SILVA et al. (2013) |
| AbM extracts | – | 156, 313, 650, and 1,250 μg/ml EE and EA (in vitro) | Antioxidant | Wei et al. (2019) |
| Lipid | Ergosterol | 10, 50, 100 and 20 mg/kg BW; intraperitoneal 100, 200, 400 and 800 mg/kg BW; oral | Antitumor | Takaku et al. (2001) |